Apr 28, 2022
Who else has to deal with allergies and medical problems 24/7 everyday of every month of every year.
seen from China
seen from Germany
seen from China
seen from China
seen from South Korea
seen from Germany
seen from United States
seen from China
seen from Belgium
seen from Germany
seen from Spain
seen from Italy
seen from Italy
seen from Italy
seen from Italy
seen from Türkiye
seen from Kosovo
seen from Italy
seen from Italy
seen from India
Who else has to deal with allergies and medical problems 24/7 everyday of every month of every year.
Post Workout with mild asthma but also reduced lung space:
Me: *out of breath, lungs hurt*
Me: *puffs inhaler*
....
Me: *still in pain*
"WTF Why?!?
My lungs: "ha we can't expand enough to get oxygen try getting a better chest bone loser :D"
Basically I've never had an asthma attack but I'll feel like shit for half an hour and an inhaler barely helps
-_-
To any of my fellow British Tumblr and followers, if you have asthma or hayfever make sure to take you tablets and inhalers. I had a massive asthma attack today!! Its very warm and the pollen count is very high ++. It's not just grass pollen. It's also tree pollens mold and fungus spores plus Giant Hogweed is growing everywhere in abundance. If you feel breathless get straight to the doctors.. My love to you all.
King-of-Comedy ❤️❤️
Asthma: A Comprehensive Guide to Understanding, Managing, and Living Well
Introduction: More Than Just Breathlessness Asthma is a chronic respiratory condition that affects millions of people worldwide, yet it remains widely misunderstood. Characterized by inflammation and narrowing of the airways, asthma can transform simple acts of breathing into a conscious struggle. This comprehensive guide delves into the intricacies of asthma, from its underlying mechanisms and…
From Concept to Commissioning: Why a Dry Powder Inhaler CDMO Accelerates Inhalation Drug Development
What makes DPI development different (and harder) than oral drugs
Developing an inhalation therapy is uniquely complex: particle engineering, device compatibility, aerosol performance and global regulatory demands all have to align. That’s why working with a DPI-focused CDMO — one with inhalation-specific technology and a Concept-to-Commissioning approach — can be the difference between a stalled project and a successful IND/CTA and commercial launch. At Vamsi Pharma (WHO-GMP; Telangana, India; founded 2015) we specialize in Dry Powder Inhaler (DPI) development, from premix design to device combo packs, analytical validation and seamless technology transfers — all engineered to preserve product performance through scale-up.
Inhalation products require precise control of particle size, moisture, dose uniformity and device-formulation interactions. A small change in particle morphology or filling process can materially change delivered dose and fine particle fraction. That technical sensitivity means standard CDMO capabilities aren’t enough — you need inhalation-specific experience in aerosol science, impactor testing, and device assembly.
The “Concept to Commissioning” advantage
Our model takes responsibility for the whole lifecycle so that the innovation you create at bench scale is the same innovation that reaches patients:
Concept & ideation: Define clinical objectives, device use case, and feasibility.
Research & formulation: Particle engineering (milling, spray-drying), carrier optimization, and premix design.
Analytical readiness: Stability-indicating assays, cascade impactor/APS testing, method validation (ICH Q2(R1)).
Clinical & commercial manufacturing: Clinical supplies, capsule/reservoir filling, device assembly, serialization.
Technology transfer & commissioning: Transfer master plans, PPQ support, training, and post-transfer troubleshooting.
This continuity reduces handoffs, compresses timelines, and lowers regulatory risk.
Services that directly solve your pain points
Premix & bulk capsules — ready-to-fill premixes engineered for dose consistency and flowability.
Finished dose options — DPI formulations supplied with or without device; device combo packs with human-factors informed prototypes.
Analytical method dev & validation — potency, impurities, APSD, delivered dose uniformity, LOD/LOQ, and method transfers to QC.
Manufacturing technologies — controlled jet milling, spray-drying, low-humidity premix production, precision metering, automated device assembly & in-line inspection.
Technology transfer — validated transfer protocols, engineering runs, SOPs, and training to preserve performance across sites.
Regulatory support — CMC packages, stability data, risk assessments, and lot release testing for global filings.
Quality, compliance and patient safety (non-negotiable)
Operating from a WHO-GMP certified facility, we maintain validated environmental suites, cleaning/containment systems and serialization options. Child-resistant and tamper-evident designs are available where required. Our QA oversight ensures audit readiness and defensible data for regulatory submissions.
Choosing the right DPI CDMO: a 7-point checklist
Inhalation-specific experience (DPI projects, not just general solid-dose work).
Analytical capability (cascade impactor, APSD, method validation).
Manufacturing technology (jet milling, spray-drying, automated assembly).
WHO-GMP facility and regulatory track record.
Technology transfer capability and documented TMF.
Human factors & device ergonomics expertise.
Single-vendor accountability (from premix to commissioning).
If a potential partner fails any one of these, you’re taking avoidable risk.
How we prove value to partners (what you should expect)
Transparent project governance and milestones from feasibility to PPQ.
Practical risk assessments and DOE-driven process definition.
Analytical transfers, instrument qualification, and LIMS-ready data.
Post-market monitoring support and iterative lifecycle improvements.
Dupixent 300 mg Injection
Dupixent 300 mg Injection contains Dupilumab, a prescription monoclonal antibody that targets and inhibits specific proteins involved in inflammation. It is widely used in the treatment of moderate-to-severe atopic dermatitis (eczema), uncontrolled asthma, and chronic rhinosinusitis with nasal polyps (CRSwNP).
By blocking interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling pathways, Dupixent helps reduce inflammation, improve skin condition, ease breathing, and decrease nasal congestion and polyps.
Medical Uses of Dupixent Injection:
Atopic Dermatitis (Eczema): Reduces itching, redness, and flare-ups.
Asthma: Improves lung function and reduces the risk of asthma attacks in patients with severe or uncontrolled asthma.
Chronic Rhinosinusitis with Nasal Polyps: Shrinks polyps, relieves congestion, and improves breathing.
Key Benefits:
Effective biologic therapy for multiple inflammatory conditions
Long-lasting relief with biweekly injections
Reduces dependence on corticosteroids
Improves overall quality of life
How to Use: Dupixent 300 mg Injection is given subcutaneously (under the skin) every two weeks, or as prescribed by your doctor. Patients may be trained to self-administer at home under medical guidance.
Possible Side Effects: Injection site reactions, conjunctivitis, eye irritation, allergic reactions, and cold sores. In rare cases, severe allergic responses may occur. > https://www.drugsgeneral.com/dupixent-300-mg-injection/
Top Pulmonology Treatments in 2025: Innovations with High Impact Factor in Global Healthcare
Pulmonology in 2025 is moving ahead quickly with advanced treatments for chronic lung problems like asthma, COPD, and lung fibrosis. The latest focus is on non-invasive methods, AI-powered diagnostic tools, and personalised treatment plans. These modern approaches are helping patients recover faster and live healthier lives.
Several pulmonology breakthroughs published in impact factor journals are now shaping the future of global healthcare. Treatments such as robotic-assisted bronchoscopy, gene-based therapies, and targeted drug delivery are already showing positive results in clinical research.
Today, doctors are relying more on high-impact research to make accurate treatment decisions. These well-respected studies offer trustworthy, evidence-based information that supports both medical professionals and patients.
As we go through 2025, the strong combination of technology and scientific research is creating a new benchmark in respiratory care. With these exciting developments, the future of lung health is becoming more advanced, reliable, and hopeful than ever.